Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941
In development [GID-TA10832] Expected publication date: TBC
Search results
541 results
-
-
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant [ID3969]
In development [GID-TA10852] Expected publication date: TBC
-
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [Review of TA611] [ID4069]
In development [GID-TA10985] Expected publication date: TBC
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
In development [GID-TA10979] Expected publication date: TBC
-
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
In development [GID-TA10696] Expected publication date: TBC
-
Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]
In development [GID-TA10892] Expected publication date: TBC
-
Foslevodopa-foscarbidopa for treating Parkinson's disease with motor symptoms [ID3876]
In development [GID-TA10772] Expected publication date: 03 May 2023
-
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
In development [GID-TA10948] Expected publication date: TBC
-
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]
In development [GID-TA10785] Expected publication date: 16 November 2022
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
In development [GID-TA10763] Expected publication date: TBC
-
Gefapixant for treating refractory or unexplained chronic cough [ID3789]
In development [GID-TA10678] Expected publication date: TBC
-
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]
In development [GID-TA10801] Expected publication date: TBC
-
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]
In development [GID-TAG456] Expected publication date: TBC
-
Venous thromboembolism - apixaban (acute medical illness) [ID310]
In development [GID-TAG419] Expected publication date: TBC
-
Venous thromboembolism (prevention) - rivaroxaban [ID463]
In development [GID-TAG427] Expected publication date: TBC
-
Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264
In development [GID-TA10365] Expected publication date: TBC
-
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250
In development [GID-TA10213] Expected publication date: TBC
-
Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair
In development [GID-IPG10191] Expected publication date: TBC
-
Sternoclavicular joint replacement for arthritis
In development [GID-IPG10199] Expected publication date: TBC
-
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
In development [GID-TA10577] Expected publication date: 21 April 2021
-
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]
In development [GID-TA10760] Expected publication date: TBC
-
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]
In development [GID-TA10761] Expected publication date: TBC
-
Total hip arthroplasty using the superpath approach for osteoarthritis
In development [GID-IPG10204] Expected publication date: TBC
-
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
In development [GID-TA10464] Expected publication date: TBC
-
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]
In development [GID-TA10591] Expected publication date: TBC
-
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260
In development [GID-TA10309] Expected publication date: TBC
-
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]
In development [GID-TA10484] Expected publication date: TBC
-
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]
In development [GID-TA10709] Expected publication date: TBC
-
Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]
In development [GID-TA10447] Expected publication date: TBC
-
Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]
In development [GID-TA10628] Expected publication date: TBC
-
Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]
In development [GID-TA10627] Expected publication date: TBC
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
In development [GID-TA10329] Expected publication date: TBC
-
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development [GID-TA10250] Expected publication date: TBC
-
Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]
In development [GID-TA10634] Expected publication date: TBC
-
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
In development [GID-TA10615] Expected publication date: TBC
-
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
In development [GID-TA10375] Expected publication date: TBC
-
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
In development [GID-TA10259] Expected publication date: TBC
-
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
In development [GID-TA10631] Expected publication date: TBC
-
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
In development [GID-TA10320] Expected publication date: TBC
-
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
In development [GID-TA10620] Expected publication date: TBC
-
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940
In development [GID-TA10397] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
In development [GID-TA10148] Expected publication date: TBC
-
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470
In development [GID-TA10354] Expected publication date: TBC
-
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
In development [GID-TA10480] Expected publication date: TBC
-
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
In development [GID-TA10546] Expected publication date: TBC
-
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
In development [GID-TA10542] Expected publication date: TBC
-
Implantable Vagus Nerve Stimulator in Heart Failure
In development [GID-IP1145] Expected publication date: TBC
-
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
In development [GID-TA10211] Expected publication date: TBC
-
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development [GID-TA10573] Expected publication date: TBC